Irreversible Electroporation of Hepatic Malignancy

Abstract

Hepatocellular carcinoma (HCC) is a worldwide problem of epidemic proportions, best treated in a multidisciplinary setting. Major advances have been made in all specialties that manage patients with HCC, with surgical options at one end of the spectrum and palliative chemotherapy on the other, and the vast majority of patients require the involvement and expertise of interventional oncology. Several ablative and transarterial technologies are currently available. Irreversible electroporation (IRE) is a new ablative technology that uses high-voltage, low-energy DC current to create nanopores in the cell membrane, disrupting the homeostasis mechanism and inducing cell death by initiating apoptosis. This article discusses the evolution of IRE as well as its safety and efficacy in the context of other ablative therapies in the treatment of hepatic malignancies.

Keywords

irreversible electroporation (IRE) - NanoKnife - hepatocellular carcinoma (HCC) ablation - apoptosis

• References

• 1 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2) 74-108
• 2 Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 (Suppl. 01) S20-S37
• 3 Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127 (5) (Suppl. 01) S5-S16
• 4 Seeff LB. Introduction: the burden of hepatocellular carcinoma. Gastroenterology 2004; 127 (5) (Suppl. 01) S1-S4
• 5 Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127 (5) 1372-1380
• 6 Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54 (4) 533-539
• 7 Llovet JM, Ricci S, Mazzaferro V , et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (4) 378-390
• 8 Rodrıguez de Lope C, Tremosini S, Forner A , et al. Management of HCC. J Hepatol 2012; 56 (6) 1317-1323
• 9 Figueras J, Jaurrieta E, Valls C , et al. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg 2000; 190 (5) 580-587
• 10 Yao FY, Bass NM, Nikolai B , et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002; 8 (10) 873-883
• 11 Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42 (5) 1208-1236
• 12 Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009; 49 (2) 453-459
• 13 Teratani T, Yoshida H, Shiina S , et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology 2006; 43 (5) 1101-1108
• 14 Mahvi DM, Lee Jr FT. Radiofrequency ablation of hepatic malignancies: is heat better than cold?. Ann Surg 1999; 230 (1) 9-11
• 15 Nahum Goldberg S, Dupuy DE. Image-guided radiofrequency tumor ablation: challenges and opportunities—part I. J Vasc Interv Radiol 2001; 12 (9) 1021-1032
• 16 Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1982; 1: 841-845
• 17 Okino M, Mohri H. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res 1987; 78 (12) 1319-1321
• 18 Mir LM, Orlowski S, Belehradek Jr J, Paoletti C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 1991; 27 (1) 68-72
• 19 Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng 2005; 33 (2) 223-231
• 20 Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality—clinical implications. Technol Cancer Res Treat 2007; 6 (1) 37-48
• 21 Lee EW, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology 2010; 255 (2) 426-433
• 22 Thomson KR, Cheung W, Ellis SJ , et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 2011; 22 (5) 611-621
• 23 Narayanan G, Froud T, Lo K, Barbery KJ, Perez-Rojas E, Yrizarry J. Pain analysis in patients with hepatocellular carcinoma: irreversible electroporation versus radiofrequency ablation—initial observations. Cardiovasc Intervent Radiol 2012; ; June 30 (Epub ahead of print)
• 24 Kingham TP, Karkar AM, D'Angelica MI , et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg 2012; 215 (3) 379-387
• 25 Narayanan G, Hosein P, Arora G, Barbery KJ, Yrizarry J. Percutaneous irreversible electroporation (ire) in the treatment of HCC and metastatic colorectal cancer (MCRC) to the liver. J Vasc Interv Radiol 2012; 23 (12) 1613-1621
• 26 El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127 (5) (Suppl. 01) S27-S34
• 27 El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139 (10) 817-823